$CBIS is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
(0)
(0)
Deliver breaking news, insightful commentary, and exclusive reports. Get in touch
benzingaheadline@gmail.com.
Target readers who trust our platform to stay ahead of the curve.